Literature DB >> 3056930

Synthetic peptides as substrates and inhibitors of human immune deficiency virus-1 protease.

S Billich1, M T Knoop, J Hansen, P Strop, J Sedlacek, R Mertz, K Moelling.   

Abstract

Retroviruses code for a virus-specific protease which is essential for polyprotein processing and viral infectivity. The human immune deficiency virus-1 protease is an aspartic protease of 9 kDa which was synthesized by recombinant DNA technology and arises by autocatalytic processing from a polyprotein precursor which has recently been demonstrated by use of a protease-specific monoclonal antibody. The protease was shown to form dimers. Here we demonstrate that synthetic peptides can be used as both model substrates as well as inhibitors for investigation of the protease. 14 synthetic peptides, 7-18 amino acids in length, containing putative protease cleavage sites of the viral polyprotein gag and pol precursors, have been analyzed with the partially purified protease by the use of high performance liquid chromatography. In seven cases, where cleavage was observed, the length of the peptides did not significantly influence the cleavage efficiencies, heptapeptides being large enough as model substrates. No cleavage was observed with a protein preparation purified in parallel from control bacteria not expressing the human immune deficiency virus-1 protease. The protease was not only able to cut next to a proline but also between other peptides indicating that the proline is not a prerequisite. Three peptides with either reduced bonds at the cleavage site or a substitution by statin were inhibitory while another uncleaved substrate was not. The usefulness of small model substrates for characterization of the protease is further demonstrated by determination of a kinetic optimum pH (3.5-5.5) and incubation temperature (37 degrees C).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3056930

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

1.  The dimer interfaces of protease and extra-protease domains influence the activation of protease and the specificity of GagPol cleavage.

Authors:  Steven C Pettit; Sergei Gulnik; Lori Everitt; Andrew H Kaplan
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor.

Authors:  A L Swain; M M Miller; J Green; D H Rich; J Schneider; S B Kent; A Wlodawer
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

3.  Mutagenesis of protease cleavage sites in the human immunodeficiency virus type 1 gag polyprotein.

Authors:  R J Tritch; Y E Cheng; F H Yin; S Erickson-Viitanen
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

4.  Isolation and characterization of recombinant Drosophila Copia aspartic proteinase.

Authors:  Senarath B P Athauda; Katsuji Yoshioka; Tadayoshi Shiba; Kenji Takahashi
Journal:  Biochem J       Date:  2006-11-01       Impact factor: 3.857

5.  Development of a novel anti-HIV-1 agent from within: effect of chimeric Vpr-containing protease cleavage site residues on virus replication.

Authors:  D Serio; T A Rizvi; M Cartas; V S Kalyanaraman; I T Weber; H Koprowski; A Srinivasan
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

Review 6.  Expression of virus-encoded proteinases: functional and structural similarities with cellular enzymes.

Authors:  W G Dougherty; B L Semler
Journal:  Microbiol Rev       Date:  1993-12

7.  Mutational analysis of a native substrate of the human immunodeficiency virus type 1 proteinase.

Authors:  K Partin; H G Kräusslich; L Ehrlich; E Wimmer; C Carter
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

8.  Isolation of mutants of human immunodeficiency virus protease based on the toxicity of the enzyme in Escherichia coli.

Authors:  E Z Baum; G A Bebernitz; Y Gluzman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

9.  Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease.

Authors:  Steve C Pettit; Gavin J Henderson; Celia A Schiffer; Ronald Swanstrom
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions.

Authors:  S C Pettit; M D Moody; R S Wehbie; A H Kaplan; P V Nantermet; C A Klein; R Swanstrom
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.